Send to

Choose Destination
Nat Commun. 2017 Feb 16;8:14450. doi: 10.1038/ncomms14450.

A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis.

Author information

Department of Molecular Medicine, Cornell University, Ithaca, New York 14853, USA.
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA.
Department of Biomedical Sciences, Cornell University, Ithaca, New York 14853, USA.
Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, USA.


Non-classical secretory vesicles, collectively referred to as extracellular vesicles (EVs), have been implicated in different aspects of cancer cell survival and metastasis. Here, we describe how a specific class of EVs, called microvesicles (MVs), activates VEGF receptors and tumour angiogenesis through a unique 90 kDa form of VEGF (VEGF90K). We show that VEGF90K is generated by the crosslinking of VEGF165, catalysed by the enzyme tissue transglutaminase, and associates with MVs through its interaction with the chaperone Hsp90. We further demonstrate that MV-associated VEGF90K has a weakened affinity for Bevacizumab, causing Bevacizumab to be ineffective in blocking MV-dependent VEGF receptor activation. However, treatment with an Hsp90 inhibitor releases VEGF90K from MVs, restoring the sensitivity of VEGF90K to Bevacizumab. These findings reveal a novel mechanism by which cancer cell-derived MVs influence the tumour microenvironment and highlight the importance of recognizing their unique properties when considering drug treatment strategies.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center